JP2007516193A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007516193A5 JP2007516193A5 JP2006518324A JP2006518324A JP2007516193A5 JP 2007516193 A5 JP2007516193 A5 JP 2007516193A5 JP 2006518324 A JP2006518324 A JP 2006518324A JP 2006518324 A JP2006518324 A JP 2006518324A JP 2007516193 A5 JP2007516193 A5 JP 2007516193A5
- Authority
- JP
- Japan
- Prior art keywords
- symptom
- condition
- composition
- bipolar
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 239000000203 mixture Substances 0.000 claims 12
- 208000024891 symptom Diseases 0.000 claims 9
- JLOAJISUHPIQOX-UHFFFAOYSA-N Norquetiapine Chemical compound C1CNCCN1C1=NC2=CC=CC=C2SC2=CC=CC=C12 JLOAJISUHPIQOX-UHFFFAOYSA-N 0.000 claims 6
- 208000020925 Bipolar disease Diseases 0.000 claims 5
- 150000003839 salts Chemical class 0.000 claims 4
- 208000019901 Anxiety disease Diseases 0.000 claims 3
- 206010026749 Mania Diseases 0.000 claims 3
- 208000019022 Mood disease Diseases 0.000 claims 3
- 208000028017 Psychotic disease Diseases 0.000 claims 3
- 230000036506 anxiety Effects 0.000 claims 3
- 208000028683 bipolar I disease Diseases 0.000 claims 3
- 208000025307 bipolar depression Diseases 0.000 claims 3
- 201000000980 schizophrenia Diseases 0.000 claims 3
- 208000028698 Cognitive impairment Diseases 0.000 claims 2
- 206010012289 Dementia Diseases 0.000 claims 2
- 208000010877 cognitive disease Diseases 0.000 claims 2
- 208000015122 neurodegenerative disease Diseases 0.000 claims 2
- 239000008203 oral pharmaceutical composition Substances 0.000 claims 2
- 150000001875 compounds Chemical class 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000012458 free base Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US48436503P | 2003-07-02 | 2003-07-02 | |
| PCT/GB2004/002783 WO2005002586A1 (en) | 2003-07-02 | 2004-06-28 | Metabolite of quetiapine |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2007516193A JP2007516193A (ja) | 2007-06-21 |
| JP2007516193A5 true JP2007516193A5 (enExample) | 2007-08-16 |
Family
ID=33563981
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006518324A Ceased JP2007516193A (ja) | 2003-07-02 | 2004-06-28 | クエチアピンの代謝産物 |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US20050026900A1 (enExample) |
| EP (1) | EP1644005B1 (enExample) |
| JP (1) | JP2007516193A (enExample) |
| KR (1) | KR20060082037A (enExample) |
| CN (1) | CN1816339B (enExample) |
| AR (1) | AR045004A1 (enExample) |
| AT (1) | ATE477803T1 (enExample) |
| AU (1) | AU2004253334A1 (enExample) |
| BR (1) | BRPI0412127A (enExample) |
| CA (1) | CA2531284A1 (enExample) |
| DE (1) | DE602004028739D1 (enExample) |
| ES (1) | ES2349091T3 (enExample) |
| IL (1) | IL172616A0 (enExample) |
| IS (1) | IS8283A (enExample) |
| MX (1) | MXPA05013869A (enExample) |
| NO (1) | NO20060556L (enExample) |
| RU (1) | RU2005141060A (enExample) |
| TW (1) | TW200509944A (enExample) |
| UY (1) | UY28400A1 (enExample) |
| WO (1) | WO2005002586A1 (enExample) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4414237B2 (ja) * | 2002-03-20 | 2010-02-10 | テバ ファーマシューティカル インダストリーズ リミティド | ケチアピンヘミフマレートの結晶形 |
| BRPI0417749A (pt) | 2003-12-22 | 2007-04-10 | Acadia Pharm Inc | composto, método de sintese de composto, bibliotecas combinatórias, composições farmacêuticas e métodos de tratamento de disfunções neuropsiquiátricas |
| WO2008021463A2 (en) * | 2006-08-15 | 2008-02-21 | Acadia Pharmaceuticals, Inc. | Amino substituted diaryl[a,d]cycloheptene analogs as muscarinic agonists and methods of treatment of neuropsychiatric disorders |
| US20060081361A1 (en) * | 2004-09-13 | 2006-04-20 | Gabbey Lawrence W | Oil cooler with integral filter |
| EP1838325A1 (en) * | 2005-01-07 | 2007-10-03 | AstraZeneca AB | NEW USE OF 11-PIPERAZIN-1-YLDIBENZO [b,f][1,4]THIAZEPINE OR ITS PHARMACEUTICALLY ACCEPTABLE SALT AND TO ORAL PHARMACEUTICAL COMPOSITIONS |
| US20060252744A1 (en) * | 2005-04-04 | 2006-11-09 | Burstein Ethan S | Use of N-desmethylclozapine and related compounds as dopamine stabilizing agents |
| JP2008502707A (ja) * | 2005-04-14 | 2008-01-31 | テバ ファーマシューティカル インダストリーズ リミティド | クエチアピンフマレートの調製方法 |
| WO2007004234A1 (en) * | 2005-07-04 | 2007-01-11 | Usv Limited | A PROCESS FOR THE PREPARATION OF 2-[2-(4-DIBENZO[b,f] [L,4] THIAZEPIN-11-yl-1- PIPERAZINYL)ETHOXY] ETHANOL FUMARATE |
| EP1951694A4 (en) * | 2005-11-18 | 2010-09-22 | Astrazeneca Ab | FORMS OF SALTS |
| US8389510B2 (en) | 2005-11-18 | 2013-03-05 | Astrazeneca Ab | Crystalline forms |
| WO2007062338A2 (en) * | 2005-11-18 | 2007-05-31 | Astrazeneca Ab | Solid formulations |
| JP2009516708A (ja) * | 2005-11-18 | 2009-04-23 | アストラゼネカ・アクチエボラーグ | 液体製剤 |
| EP1951257A4 (en) * | 2005-11-18 | 2008-11-05 | Astrazeneca Ab | CRYSTALLINE FORMS |
| WO2008118141A2 (en) * | 2006-10-17 | 2008-10-02 | Acadia Pharmaceuticals Inc. | Use of cannabinoid modulating compounds in combination with other therapeutic compounds for adjunctive therapy |
| JP2010514682A (ja) * | 2006-12-20 | 2010-05-06 | アストラゼネカ・アクチエボラーグ | 化合物及びその使用 |
| JP2010514684A (ja) * | 2006-12-20 | 2010-05-06 | アストラゼネカ・アクチエボラーグ | 化合物及びその使用 |
| CN101616661A (zh) * | 2006-12-20 | 2009-12-30 | 阿斯利康(瑞典)有限公司 | 化合物及其用途 |
| CN101641101A (zh) * | 2007-03-22 | 2010-02-03 | 阿斯利康(瑞典)有限公司 | 治疗心境障碍的方法 |
| CN107714703A (zh) | 2009-12-31 | 2018-02-23 | 凯姆制药公司 | 喹硫平的氨基酸缀合物、其制备和使用方法 |
| RS58335B1 (sr) | 2010-03-11 | 2019-03-29 | Kempharm Inc | Konjugati kvetiapina sa masnom kiselinom, proces za njihovo dobijanje i njihova primena |
| CN102552128B (zh) * | 2012-02-28 | 2013-09-18 | 陆荣政 | 一种富马酸喹硫平注射液及其制备方法 |
| US9993486B1 (en) | 2017-06-19 | 2018-06-12 | Tlc Therapeutics, Llc | Oral quetiapine suspension formulations with extended shelf life and enhanced bioavailability |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL140242B (nl) * | 1963-03-01 | 1973-11-15 | Wander Ag Dr A | Werkwijze voor het bereiden van op de 11-plaats door een basische groep gesubstitueerde dibenz (b.f.)(1.4) oxazepinen. |
| GB1192812A (en) * | 1966-05-20 | 1970-05-20 | American Cyanamid Co | 2-Chloro-11-(1-Piperazinyl)Dibenz[b,f]-[1,4]Oxazepine, Non-Toxic Acid Addition Salts thereof, and Therapeutic Compositions containing said Oxazepine or Salts |
| US3539573A (en) * | 1967-03-22 | 1970-11-10 | Jean Schmutz | 11-basic substituted dibenzodiazepines and dibenzothiazepines |
| US3966949A (en) * | 1973-10-12 | 1976-06-29 | Richardson-Merrell Inc. | Pharmaceutical compositions and preparing same |
| GB8607684D0 (en) * | 1986-03-27 | 1986-04-30 | Ici America Inc | Thiazepine compounds |
| US5750566A (en) * | 1994-08-12 | 1998-05-12 | Eli Lilly And Company | Synthetic excitatory amino acids |
| US6342488B1 (en) * | 1998-08-18 | 2002-01-29 | Sepracor, Inc. | Phosphonorisperidone and sulforisperidone compositions and methods |
| WO2004064753A2 (en) * | 2003-01-23 | 2004-08-05 | Acadia Pharmaceuticals Inc | Use of n-desmethylclozapine to treat human neuropsychiatric disease |
-
2004
- 2004-06-28 BR BRPI0412127-9A patent/BRPI0412127A/pt not_active IP Right Cessation
- 2004-06-28 JP JP2006518324A patent/JP2007516193A/ja not_active Ceased
- 2004-06-28 CA CA002531284A patent/CA2531284A1/en not_active Abandoned
- 2004-06-28 RU RU2005141060/15A patent/RU2005141060A/ru not_active Application Discontinuation
- 2004-06-28 ES ES04743131T patent/ES2349091T3/es not_active Expired - Lifetime
- 2004-06-28 WO PCT/GB2004/002783 patent/WO2005002586A1/en not_active Ceased
- 2004-06-28 CN CN2004800188710A patent/CN1816339B/zh not_active Expired - Fee Related
- 2004-06-28 EP EP04743131A patent/EP1644005B1/en not_active Expired - Lifetime
- 2004-06-28 MX MXPA05013869A patent/MXPA05013869A/es not_active Application Discontinuation
- 2004-06-28 KR KR1020057025264A patent/KR20060082037A/ko not_active Withdrawn
- 2004-06-28 DE DE602004028739T patent/DE602004028739D1/de not_active Expired - Lifetime
- 2004-06-28 AT AT04743131T patent/ATE477803T1/de not_active IP Right Cessation
- 2004-06-28 AU AU2004253334A patent/AU2004253334A1/en not_active Abandoned
- 2004-07-01 US US10/883,024 patent/US20050026900A1/en not_active Abandoned
- 2004-07-02 AR ARP040102345A patent/AR045004A1/es not_active Application Discontinuation
- 2004-07-02 UY UY28400A patent/UY28400A1/es not_active Application Discontinuation
- 2004-07-02 TW TW093120058A patent/TW200509944A/zh unknown
-
2005
- 2005-12-15 IL IL172616A patent/IL172616A0/en unknown
-
2006
- 2006-02-01 IS IS8283A patent/IS8283A/is unknown
- 2006-02-02 NO NO20060556A patent/NO20060556L/no not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009524676A5 (enExample) | ||
| RU2005141060A (ru) | Метаболит кветиапина | |
| JP2005500357A5 (enExample) | ||
| JP2003503454A5 (enExample) | ||
| WO2007058602A3 (en) | Novel 2-amino-imidazole-4-one compounds and their use in the manufacture of a medicament to be used in the treatment of cognitive impairment, alzheimer’s disease, neurodegeneration and dementia. | |
| FR16C0029I2 (fr) | Combinaisons medicamenteuses contenant de la benzoxazine pour traiter des maladies des voies respiratoires | |
| MX2011011489A (es) | Derivados de isoxazol-piridina. | |
| HRP20110570T1 (hr) | Amidi diazabicikloalkana selektivni na podvrstu nikotinskih acetilkolinskih receptora | |
| JP2011522816A5 (enExample) | ||
| NZ593467A (en) | Treatment of cognitive disorders with (r)-7-chloro-n-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide and pharmaceutically acceptable salts thereof | |
| TW200635923A (en) | Tricyclic heterocycles, their manufacture and use as pharmaceutical agents | |
| JP2015524444A5 (enExample) | ||
| SE0104341D0 (sv) | New use | |
| MX2011011273A (es) | Derivados de isoxazol-pirazol. | |
| JP2009541443A5 (enExample) | ||
| MX2011011477A (es) | Derivados de isoxazol-piridazina. | |
| WO2005089753A3 (en) | Daao inhibiting bξnzisoxazoles and their use for the treatment of mental disorders | |
| JP2007513993A5 (enExample) | ||
| JP2008513510A5 (enExample) | ||
| WO2007038112A3 (en) | Combination of rosiglitazone and donepezil for improvement of cognitive function | |
| JP2007509960A5 (enExample) | ||
| MX2011011490A (es) | Derivados de isoxazol-tiazol como agonistas inversos del receptor de acido gamma-aminobutirico a (gaba a), para usarse en el tratamiento de trastornos cognitivos. | |
| JP2011524898A5 (enExample) | ||
| JP2011519873A5 (enExample) | ||
| WO2004082584A3 (en) | 5ht2c receptor antagonists in the treatment of schizophrenia |